المؤلفون: Ciardiello D., Famiglietti V., Napolitano S., Esposito L., Normanno N., Avallone A., Latiano T., Maiello E., Pietrantonio F., Cremolini C., Santabarbara G., Pinto C., Troiani T., Martinelli E., Ciardiello F., Martini G.

المساهمون: Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T., Maiello, E., Pietrantonio, F., Cremolini, C., Santabarbara, G., Pinto, C., Troiani, T., Martinelli, E., Ciardiello, F., Martini, G.

مصطلحات موضوعية: Immunotherapy, MCRC, Rechallenge anti‐EGFR, Skin toxicity

الوصف: The single‐arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild‐type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first‐line anti‐EGFR‐based chemotherapy, who progressed and received a subsequent line of therapy. The correlation of skin toxicity (ST) and different clinicomolecular variables with overall survival (OS), progression‐free survival (PFS) and response rate (RR) was assessed at univariate and multivariate analysis. A total of 33/77 (42.9%) patients experienced grade 2–3 ST and displayed median OS (mOS) of 17.8 months (CI 95%, 14.9–20.6); whereas 44/77 (57.1%) patients with grade 0–1 ST exhibited mOS of 8.2 months (CI 95%, 5.5–10.9), (hazard ratio (HR), 0.51; CI 95%, 0.29–0.89; p = 0.019). Median PFS (mPFS) was 4.6 months (CI 95%, 3.4–5.7) in patients with grade 2–3 ST, compared to patients with grade 0–1 ST with mPFS of 3.4 months (CI 95%, 2.7–4.1; HR, 0.49; CI 95%, 0.3–0.8; p = 0.004). Grade 2–3 ST (HR, 0.51; CI 95%, 0.29– 0.89; p = 0.019) and RAS/BRAF/EGFR WT circulating tumor DNA (ctDNA) (HR, 0.50; CI 95%, 0.27– 0.9; p = 0.019) had a statistically significant effect on OS at univariate analysis. At the multivariate analysis, RAS/BRAF/EGFR WT ctDNA status maintained statistical significance (HR, 0.49; CI 95%, 0.27–0.9; p = 0.023), whereas there was a trend towards ST grade 2–3 (HR, 0.54; CI 95%, 0.29–1.01; p = 0.054). Skin toxicity is a promising biomarker to identify patients with mCRC that could benefit of anti‐EGFR rechallenge.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34830870; info:eu-repo/semantics/altIdentifier/wos/WOS:000723622100001; volume:13; issue:22; numberofpages:12; journal:CANCERS; https://hdl.handle.net/11568/1113672Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85118929902; https://www.mdpi.com/2072-6694/13/22/5715Test

الإتاحة: https://doi.org/10.3390/cancers13225715Test
https://hdl.handle.net/11568/1113672Test
https://www.mdpi.com/2072-6694/13/22/5715Test

المؤلفون: Ottaviano, M, Curvietto, M, Rescigno, P, Tortora, M, Palmieri, G, Giannarelli, D, Aieta, M, Assalone, P, Attademo, L, Avallone, A, Bloise, F, Bosso, D, Borzillo, V, Buono, G, Calderoni, G, Caputo, F, Cartenì, G, Cavallero, D, Cavo, A, Ciardiello, F, Conca, R, Conteduca, V, De Falco, S, De Felice, M, De Laurentiis, M, De Placido, P, De Placido, S, De Santo, I, De Stefano, A, Della Corte, CM, Di Franco, R, Di Lauro, V, Fabbrocini, A, Federico, P, Festino, L, Giordano, P, Giuliano, M, Gridelli, C, Grimaldi, AM, Lia, M, Marretta, AL, Massa, V, Mennitto, A, Merler, S, Merz, V, Messina, C, Messina, M, Milano, M, Minisini, AM, Montesarchio, V, Morabito, A, Morgillo, F, Mucci, B, Nappi, L, Napolitano, F, Paciolla, I, Pagliuca, M, Parola, S, Pepe, S, Petrillo, A, Piantedosi, F, Piccin, L, Picozzi, F, Pietroluongo, E, Pignata, S, Prati, V, Riccio, V, Rosanova, M, Rossi, A, Russo, A, Salati, M, Santabarbara, G, Sbrana, A, Simeone, E, Silvestri, A, Spada, M, Tarantino, P, Taveggia, P, Tomei, F, Vincenzo, T, Trapani, D, Trojanello, C, Vanella, V, Vari, S, Ventriglia, J, Vitale, MG, Vitiello, F, Vivaldi, C, von Arx, C, Zacchi, F, Zampiva, I, Zivi, A, Daniele, B, Ascierto, PA, SCITO (Società Campana di ImmunoTerapia Oncologica)

المساهمون: Rescigno, Pasquale

مصطلحات موضوعية: SCITO (Società Campana di ImmunoTerapia Oncologica), Humans, Pneumonia, Viral, Coronavirus Infections, Neoplasms, Prevalence, Medical Oncology, Infection Control, Geography, Adult, Italy, Female, Male, Drug Prescriptions, Pandemics, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Time-to-Treatment, Surveys and Questionnaires, Practice Patterns, Physicians', Oncologists, Betacoronavirus, Antineoplastic Agents, Immunological, B7-H1 Antigen, COVID-19, SARS-CoV-2

الوصف: BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. METHODS: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options. RESULTS: This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. CONCLUSION: Our study highlights the efforts of Italian oncologists to maintain high standards of care ...

وصف الملف: Print; application/pdf

العلاقة: Journal for immunotherapy of cancer, 2020, 8 (2); https://repository.icr.ac.uk/handle/internal/4346Test

الإتاحة: https://doi.org/10.1136/jitc-2020-001154Test
https://repository.icr.ac.uk/handle/internal/4346Test

المؤلفون: Ciardiello, D., Famiglietti, V., Napolitano, S., Terminiello, M., Borrelli, C., Vitiello, P., Pietrantonio, F., Avallone, A., Normanno, N., Maiello, E., Latiano, T., Cremolini, C., Santabarbara, G., Pinto, C., Santini, D., Esposito, L., Di Liello, A., Troiani, T., Ciardiello, F., Martinelli, E., Martini, G.

المصدر: Annals of Oncology ; volume 32, page S167-S168 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.05.254Test
https://api.elsevier.com/content/article/PII:S0923753421014435?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421014435?httpAccept=text/plainTest

المؤلفون: Martinelli, E., Martini, G., Troiani, T., Pietrantonio, F., Avallone, A., Normanno, N., Nappi, A., Maiello, E., Falcone, A., Santabarbara, G., Pinto, C., Santini, D., Ciardiello, D., Terminiello, M., Borrelli, C., Napolitano, S., Renato, D., Famiglietti, V., Esposito, L., Ciardiello, F.

المصدر: Annals of Oncology ; volume 31, page S409-S410 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.508Test
https://api.elsevier.com/content/article/PII:S0923753420405046?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420405046?httpAccept=text/plainTest

المؤلفون: De Stefano, A., Giuliani, F., Nasti, G., Montesarchio, V., Santabarbara, G., Leo, S., Malapelle, U., Rosati, G., Lolli, I., Tamburini, E., Colombo, A., Santini, D., Silvestro, L., Leone, A., Vitagliano, C., Troncone, G., Sobrero, A., Giannarelli, D., Budillon, A., Avallone, A.

المساهمون: Amgen

المصدر: Annals of Oncology ; volume 34, page S172-S173 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2023.04.498Test
https://api.elsevier.com/content/article/PII:S0923753423006403?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753423006403?httpAccept=text/plainTest

المؤلفون: Pusceddu, V., Pretta, A., Palma, V., Dettori, M., Ziranu, P., Palmas, E., Moledda, G., Sanna, G., Codipietro, C., Donisi, C., Rizzo, D., D'Agata, A.P., Balconi, F., Mariani, S., Lai, E., Puzzoni, M., Mascia, L., Santabarbara, G., Scartozzi, M.

المصدر: Annals of Oncology ; volume 34, page S1518 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2023.10.261Test
https://api.elsevier.com/content/article/PII:S0923753423044678?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753423044678?httpAccept=text/plainTest

المؤلفون: Martinelli, E., Troiani, T., Cardone, C., Ciardiello, D., Zanaletti, N., Borrelli, C., Terminiello, M., Avallone, A., Falcone, A., Maiello, E., Bordonaro, R., Santini, D., Garufi, C., Pietrantonio, F., Pinto, C., Santabarbara, G., Normanno, N., Ciardiello, F.

المصدر: Annals of Oncology ; volume 30, page v251 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1093/annonc/mdz246.145Test
https://api.elsevier.com/content/article/PII:S0923753419588883?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753419588883?httpAccept=text/plainTest
http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz246.145/30085422/mdz246.145.pdfTest

المؤلفون: Martinelli E., Martini G., Famiglietti V., Troiani T., Napolitano S., Pietrantonio F., Ciardiello D., Terminiello M., Borrelli C., Vitiello P. P., De Braud F., Morano F., Avallone A., Normanno N., Nappi A., Maiello E., Latiano T., Falcone A., Cremolini C., Rossini D., Santabarbara G., Pinto C., Santini D., Cardone C., Zanaletti N., Di Liello A., Renato D., Esposito L., Marrone F., Ciardiello F.

المساهمون: Martinelli, E., Martini, G., Famiglietti, V., Troiani, T., Napolitano, S., Pietrantonio, F., Ciardiello, D., Terminiello, M., Borrelli, C., Vitiello, P. P., De Braud, F., Morano, F., Avallone, A., Normanno, N., Nappi, A., Maiello, E., Latiano, T., Falcone, A., Cremolini, C., Rossini, D., Santabarbara, G., Pinto, C., Santini, D., Cardone, C., Zanaletti, N., Di Liello, A., Renato, D., Esposito, L., Marrone, F., Ciardiello, F.

مصطلحات موضوعية: Antibodie, Monoclonal, Humanized, Cetuximab, Female, Human, Male, Middle Aged, Proto-Oncogene Proteins p21(ras), Antineoplastic Combined Chemotherapy Protocol, Colorectal Neoplasms

الوصف: Importance: Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment with cetuximab plus avelumab with overall survival (OS) may be worthy of investigation in this setting. Objective: To assess the efficacy and safety of cetuximab rechallenge therapy plus avelumab. Design, Setting, and Participants: This single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020. Eligible patients with RAS WT mCRC had a complete or partial response to first-line chemotherapy plus anti-EGFR drugs, developed acquired resistance, and failed second-line therapy. Baseline circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R mutation analysis was done. Interventions: Patients received avelumab (10 mg/kg every 2 weeks) and cetuximab (400 mg/m2and, subsequently, 250 mg/m2weekly) until disease progression or unacceptable toxic effects. Main Outcomes and Measures: The primary end point was OS. Secondary end points were progression-free survival (PFS), overall response rate (ORR), and safety. Results: Seventy-seven patients were enrolled (42 men, 35 women; median age, 63 years); 71 had microsatellite stable tumors (MSS), 3 microsatellite instability-high tumors (MSI-H), 3 unknown. The study met the primary end point, with median OS (mOS) of 11.6 months (95% CI, 8.4-14.8 months). Median PFS (mPFS) was 3.6 months (95% CI, 3.2-4.1 months). Common grade-3 adverse events were cutaneous eruption, 11 (14%), and diarrhea, 3 (4%). For 67 of 77 (87%) patients, baseline analysis of plasma circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R variations was feasible. Forty-eight patients had WT disease, whereas 19 had mutations. Patients with RAS/BRAF WT ctDNA had mOS of 17.3 months (95% CI, 12.5-22.0 months) compared with 10.4 months (95% CI, 7.2-13.6 months) in patients with ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34382998; info:eu-repo/semantics/altIdentifier/wos/WOS:000684942000006; volume:7; issue:10; firstpage:1529-1535; journal:JAMA ONCOLOGY; https://hdl.handle.net/11573/1641802Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85113152505

الإتاحة: https://doi.org/10.1001/jamaoncol.2021.2915Test
https://hdl.handle.net/11573/1641802Test

المؤلفون: Ottaviano M., Curvietto M., Rescigno P., Tortora M., Palmieri G., Giannarelli D., Aieta M., Assalone P., Attademo L., Avallone A., Bloise F., Bosso D., Borzillo V., Buono G., Calderoni G., Caputo F., Carteni G., Cavallero D., Cavo A., Ciardiello F., Conca R., Conteduca V., De Falco S., De Felice M., De Laurentiis M., De Placido P., De Placido S., De Santo I., De Stefano A., Della Corte C. M., Di Franco R., Di Lauro V., Fabbrocini A., Federico P., Festino L., Giordano P., Giuliano M., Gridelli C., Grimaldi A. M., Lia M., Marretta A. L., Massa V., Mennitto A., Merler S., Merz V., Messina C., Messina M., Milano M., Minisini A. M., Montesarchio V., Morabito A., Morgillo F., Mucci B., Nappi L., Napolitano F., Paciolla I., Pagliuca M., Parola S., Pepe S., Petrillo A., Piantedosi F., Piccin L., Picozzi F., Pietroluongo E., Pignata S., Prati V., Riccio V., Rosanova M., Rossi A., Russo A., Salati M., Santabarbara G., Sbrana A., Simeone E., Silvestri A., Spada M., Tarantino P., Taveggia P., Tomei F., Vincenzo T., Trapani D., Trojanello C., Vanella V., Vari S., Ventriglia J., Vitale M. G., Vitiello F., Vivaldi C., Von Arx C., Zacchi F., Zampiva I., Zivi A., Daniele B., Ascierto P. A.

المساهمون: Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., Ascierto, P. A.

مصطلحات موضوعية: antineoplastic protocol, healthcare economics and organization, immunotherapy, lung neoplasm, melanoma, Adult, Antineoplastic Agents, Immunological, B7-H1 Antigen, Betacoronaviru, COVID-19, CTLA-4 Antigen, Coronavirus Infection, Drug Prescription, Female, Geography, Human, Infection Control, Italy, Male, Medical Oncology, Neoplasm, Oncologist, Pandemic, Pneumonia, Viral, Practice Patterns, Physicians', Prevalence, Programmed Cell Death 1 Receptor

الوصف: Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. Methods This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ 2 test for trends relative to the questions with 3 or more options. Results This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. Conclusion Our study highlights the efforts of Italian oncologists to maintain high standards of care ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33060148; info:eu-repo/semantics/altIdentifier/wos/WOS:000583157800005; volume:8; firstpage:e001154; lastpage:e001154; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; http://hdl.handle.net/11386/4756291Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85093476336

الإتاحة: https://doi.org/10.1136/jitc-2020-001154Test
http://hdl.handle.net/11386/4756291Test

المؤلفون: Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Cartenì G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA, SCITO (Società Campana di ImmunoTerapia Oncologica).

المساهمون: Ottaviano, M, Curvietto, M, Rescigno, P, Tortora, M, Palmieri, G, Giannarelli, D, Aieta, M, Assalone, P, Attademo, L, Avallone, A, Bloise, F, Bosso, D, Borzillo, V, Buono, G, Calderoni, G, Caputo, F, Cartenì, G, Cavallero, D, Cavo, A, Ciardiello, F, Conca, R, Conteduca, V, De Falco, S, De Felice, M, De Laurentiis, M, De Placido, P, De Placido, S, De Santo, I, De Stefano, A, Della Corte, Cm, Di Franco, R, Di Lauro, V, Fabbrocini, A, Federico, P, Festino, L, Giordano, P, Giuliano, M, Gridelli, C, Grimaldi, Am, Lia, M, Marretta, Al, Massa, V, Mennitto, A, Merler, S, Merz, V, Messina, C, Messina, M, Milano, M, Minisini, Am, Montesarchio, V, Morabito, A, Morgillo, F, Mucci, B, Nappi, L, Napolitano, F, Paciolla, I, Pagliuca, M, Parola, S, Pepe, S, Petrillo, A, Piantedosi, F, Piccin, L, Picozzi, F, Pietroluongo, E, Pignata, S, Prati, V, Riccio, V, Rosanova, M, Rossi, A, Russo, A, Salati, M, Santabarbara, G, Sbrana, A, Simeone, E, Silvestri, A, Spada, M, Tarantino, P, Taveggia, P, Tomei, F, Vincenzo, T, Trapani, D, Trojanello, C, Vanella, V, Vari, S, Ventriglia, J, Vitale, Mg, Vitiello, F, Vivaldi, C, von Arx, C, Zacchi, F, Zampiva, I, Zivi, A, Daniele, B, Ascierto, Pa, SCITO (Società Campana di ImmunoTerapia, Oncologica).

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000583157800005; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; http://hdl.handle.net/11369/407892Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85093476336

الإتاحة: http://hdl.handle.net/11369/407892Test